Greatest activity against gram-positive organisms, including:
S. aureus,
Beta-hemolytic streptococci.
Resolution of impetigo.
Eradication of S. aureus carrier state.
Classifications⬆⬇
Therapeutic Classification: anti-infectives
Pharmacokinetics⬆⬇
Absorption: Minimal systemic absorption.
Distribution: Remains in the stratum corneum after topical use for prolonged periods of time (72 hr).
Metabolism/Excretion: Metabolized in the skin, removed by desquamation.
Half-Life: 17–36 min.
Time/Action Profile⬆⬇
(anti-infective effect)
ROUTE
ONSET
PEAK
DURATION
Topical‡
unknown
3–5 days
72 hr
‡Resolution of lesions.
Patient/Family Teaching⬆⬇
Instruct patient on the correct application of mupirocin. Advise patient to apply medication exactly as directed for the full course of therapy. If a dose is missed, apply as soon as possible unless almost time for next dose. Avoid contact with eyes.
Topical Teach patient and family appropriate hygienic measures to prevent spread of impetigo.
Instruct parents to notify school nurse for screening and prevention of transmission.
Patient should consult health care professional if symptoms have not improved in 3–5 days.
Pronunciation⬆⬇
myoo-PEER-oh-sin
Code⬆
NDC Code
0029- GlaxoSmithKline LLC
0029-1526- BACTROBAN
0029-1526-11- 10 CARTON in 1 PACKAGE (0029-1526-11) > 1 TUBE in 1 CARTON (0029-1526-03) > 1 g in 1 TUBE
0029- GlaxoSmithKline LLC
0029-1527- BACTROBAN
0029-1527-22- 1 TUBE in 1 CARTON (0029-1527-22) > 15 g in 1 TUBE
0029- GlaxoSmithKline LLC
0029-1527- BACTROBAN
0029-1527-25- 1 TUBE in 1 CARTON (0029-1527-25) > 30 g in 1 TUBE
0093- Teva Pharmaceuticals USA, Inc.
0093-1010- Mupirocin
0093-1010-42- 1 TUBE in 1 CARTON (0093-1010-42) > 22 g in 1 TUBE
0168- E. Fougera and Co. a division of Fougera Pharmaceuticals Inc.
